Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 8/20 | 0.35 |
| ▸ | FLT4 | P35916 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862708 | 0.95 | CYP2C8 (0.38) | PPARGCYP2C8FLT1FLT4KDR | |
| SCHEMBL862454 | 0.95 | CYP2C8 (0.39) | PPARGCYP2C8FLT1FLT4KDR | |
| SCHEMBL862296 | 0.93 | PPARG (0.41) | PPARGCYP2C8TDP2SERPINE1KMT2A | |
| SCHEMBL862574 | 0.92 | CYP2C8 (0.41) | PPARGCYP2C8TDP2SERPINE1KMT2A | |
| SCHEMBL862460 | 0.92 | CYP2C8 (0.41) | PPARGCYP2C8FLT1FLT4KDR | |
| SCHEMBL862580 | 0.92 | CYP2C8 (0.38) | PPARGCYP2C8FLT1FLT4KDR | |
| SCHEMBL862590 | 0.92 | CYP2C8 (0.39) | PPARGCYP2C8TDP2SERPINE1KMT2A | |
| SCHEMBL862443 | 0.91 | TDP2 (0.36) | PPARGCYP2C8FLT1FLT4KDR | |
| SCHEMBL862901 | 0.91 | CYP2C8 (0.39) | PPARGCYP2C8TDP2KMT2ALOXL2 | |
| SCHEMBL862488 | 0.91 | SERPINE1 (0.38) | PPARGCYP2C8FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PPARG 4093/4885CYP2C8 847/4885FLT1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.